united states – TheNewsHub https://thenewshub.in Thu, 14 Nov 2024 20:29:25 +0000 en-US hourly 1 https://wordpress.org/?v=6.7 Landry CEO Fertitta becomes Wynn Resorts' largest individual shareholder with nearly 10% stake https://thenewshub.in/2024/11/14/landry-ceo-fertitta-becomes-wynn-resorts-largest-individual-shareholder-with-nearly-10-stake/ https://thenewshub.in/2024/11/14/landry-ceo-fertitta-becomes-wynn-resorts-largest-individual-shareholder-with-nearly-10-stake/?noamp=mobile#respond Thu, 14 Nov 2024 20:29:25 +0000 https://thenewshub.in/2024/11/14/landry-ceo-fertitta-becomes-wynn-resorts-largest-individual-shareholder-with-nearly-10-stake/

The new Wynn Casino and Lisboa Casino in Macao, China.

Bob Henry | Universal Images Group | Getty Images

Billionaire Tilman Fertitta has increased his ownership stake in Wynn Resorts to 9.9%, according to a filing with the U.S. Securities and Exchange Commission.

The filing indicates a passive position, though multiple people familiar with the matter tell CNBC they suspect Fertitta will be demanding.

Wynn’s share price popped 9% Thursday on the news, in line with its 200-day moving average. Over 20 years, the stock has exhibited lots of volatility but not as much sustained growth.

Stock Chart IconStock chart icon

Wynn stock against Marriott and Hilton.

The stock is up roughly 57% over two decades, compared to Marriott’s 20-year gains of more than 950%. Hilton, which went public in 2013, is up more than 500% since its debut.

Wynn Resorts and Fertitta declined to comment on his increased stake.

Fertitta, CEO of Landry’s, is the owner of the Houston Rockets as well as eight Golden Nugget casinos across the U.S., including downtown Las Vegas. He is planning a new 43-story casino resort on the Las Vegas Strip.

He is frequently outspoken about issues that affect Las Vegas, whether it is Formula One or historic union wage contracts. Wynn Las Vegas is the top-of-the-line, uber-luxurious resort on the Strip, and it owns two high-end resorts in Macao. Its customers are wealthier and generally shop and gamble more.

But Wynn’s third-quarter earnings missed expectations for revenue and adjusted property EBITDA in both Macao and Las Vegas, which began to show some softening after a long, hot streak.

Analysts occasionally question the company about plans to develop or sell 162 acres in Las Vegas, including a 128 acre golf course and a 38 acre parcel across from its resort complex on the Strip.

In a June note, Jefferies analyst David Katz estimated the land was worth slightly more than $2 billion, but noted there is “no evident plan for development or sale.”

Some investors have privately grumbled that Wynn is blowing its luxury brand power and best-in-class hospitality status domestically while it focuses on trying to establish a new gaming market in the Middle East.

During the company’s third-quarter earnings call earlier this month, at an investor day in October and in an interview with CNBC, Wynn CEO Craig Billings kept the spotlight on the opportunities he sees in the United Arab Emirates.

Wynn Resorts has a 40% stake in a new integrated casino resort being built in Ras Al Khaimah in the United Arab Emirates for a projected cost of $5.1 billion.

Today the stock trades for roughly 70% more than when Fertitta bought 6.9 million shares at about $54 apiece in 2022. That position gave him a 6.2% stake in the company and made him the second-largest individual shareholder in Wynn, after co-founder Elaine Wynn.

Now with his 9.9% stake, Fertitta supplants Elaine Wynn, who co-founded the company with her then-husband Steve Wynn and left its board of directors at the end of 2020.

Don’t miss these insights from CNBC PRO

Wynn CEO on consumer outlook, return of Macao and a casino in the Middle East
]]>
https://thenewshub.in/2024/11/14/landry-ceo-fertitta-becomes-wynn-resorts-largest-individual-shareholder-with-nearly-10-stake/feed/ 0
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy https://thenewshub.in/2024/11/13/healthy-returns-astrazeneca-expands-u-s-investment-plan-on-confidence-in-economy/ https://thenewshub.in/2024/11/13/healthy-returns-astrazeneca-expands-u-s-investment-plan-on-confidence-in-economy/?noamp=mobile#respond Wed, 13 Nov 2024 13:22:20 +0000 https://thenewshub.in/2024/11/13/healthy-returns-astrazeneca-expands-u-s-investment-plan-on-confidence-in-economy/

The office building of biopharmaceutical company AstraZeneca is being seen in Shanghai, China, on May 23, 2024. 

Nurphoto | Getty Images

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

AstraZeneca said it is doubling down on its investment in its U.S. business, a move that comes just one week after Donald Trump’s election win

AstraZeneca announced plans for $2 billion in new spending on research and development, bringing its total capital investment in the country to $3.5 billion by the end of 2026. The cash will be used to boost the company’s research and development, as well as its manufacturing footprint in the U.S.

The British-Swedish pharmaceutical giant expects the new investment to create more than 1,000 jobs, “contributing to the growth of the U.S. economy,” according to a release. The company said it currently has 17,800 U.S. employees working across 17 sites in 12 states. 

AstraZeneca said the expanded footprint will include a research and development center in Cambridge, Mass., manufacturing plants in Maryland and Texas and other sites at unspecified locations across the West and East coasts.

AstraZeneca called the investment the first in a series of steps toward hitting its revenue target of $80 billion by 2030 – a goal set earlier this year. 

The drugmaker is now one of the first major foreign companies to announce plans to invest in the U.S. after Trump’s victory. 

Several companies similarly announced major U.S. investments during Trump’s first term. Trump would often try to take credit for those investments, even if it was hard to prove a connection to his administration.

But AstraZeneca declined to explicitly say whether there was a link between Trump winning a second term and its increased spending in the U.S.

During a media call after the company’s earnings release Tuesday, AstraZeneca CEO Pascal Soriot said the investment is a “testimony of our confidence in the U.S. economy – of the U.S. marketplace over the next few years.”

Soriot, during a separate event in New York City on Tuesday, also told reporters that the drugmaker has been looking at the expanded investment “for a number of months.” 

A previous version of a Tuesday report from the Wall Street Journal suggested the company was motivated by other factors: A source familiar with the matter told the outlet that AstraZeneca’s new investment came in response to the election results and is a bet that a second Trump administration would amend certain elements of President Joe Biden’s signature Inflation Reduction Act, or IRA. The current version of the report no longer mentions the IRA.

That legislation, signed into law in 2022, includes provisions that aim to lower prescription drug costs for seniors, such as allowing Medicare to negotiate medication prices with manufacturers. AstraZeneca and other drugmakers have acknowledged that the IRA, particularly its Medicare price talks, is a headwind to their businesses. AstraZeneca’s diabetes treatment Farxiga was among the 10 drugs targeted in the first round of negotiations, which set new prices for 2026. 

But Soriot on Tuesday pushed back on the idea that the company’s decision was based around potential changes to the IRA. During the media event, he joked that “I sort of dream sometimes” of the IRA being repealed, “but not to that extent.” 

He also said some of the IRA’s provisions are “good things,” such as a $2,000 cap on out-of-pocket spending for Medicare Part D enrollees starting in 2025. 

Soriot said the company believes that the IRA is “here to stay,” adding the decision to boost its investment in the U.S. is “not so much” based on “policies specific to our industry.” 

“It’s more a general belief that the economy will remain strong. And if you have a strong economy, hopefully, that drives investments in innovation, sure, in our industry, but also many other industries,” he told reporters. “We want to tap into this innovation in the U.S.” 

When asked about Trump’s tariff policies, Soriot said it is “probably more relevant to other industries and certainly other companies.” 

Trump has threatened to slap a tariff of up to 60% on all goods imported to the U.S. from China. But Soriot called his tariff policy “irrelevant” to AstraZeneca because the company does not source products from China for the U.S. 

The products AstraZeneca commercializes in the U.S. are manufactured in its several plants across the country, “and we’re investing in even more now,” he told reporters. 

Feel free to send any tips, suggestions, story ideas and data to Annika at annikakim.constantino@nbcuni.com.

Summa Health, an integrated health system in Ohio, for $485 million, according to a release on Thursday.

The two organizations first announced the acquisition plans in January, but the terms were previously undisclosed. Summa said Thursday that the deal will help it eliminate $850 million in existing debt when combined with its current cash. The health system had about $859 million in debt as of Sept. 30, according to financial filings. 

Summa operates across five counties in northeast Ohio, and it supports more than 1,000 inpatient beds across its network of hospitals, community-based health centers and its multi-specialty group practice. General Catalyst laid the groundwork for the acquisition last year when it announced a new company called the Health Assurance Transformation Company, or HATCo, which it said operates on “decades-long” timelines.  

Buying a hospital is an unprecedented move in the venture industry, but the fund’s goal is not to cut costs at Summa, HATCo executives told CNBC this winter. Instead, the company will work to generate new revenue streams for Summa by bringing in new technology and models of care.

“This is not like a turnaround, this is not a distressed system,” HATCo CEO Dr. Marc Harrison said in a January interview.

The company has committed $350 million in capital funding to Summa over the first five years, which will be used to invest in tech and ensure the health system has the resources it needs for routine workflows, according to Thursday’s release. HATCo has also committed an additional $200 million over the first seven years, which is intended “for strategic and transformative investments.”

HATCo will evaluate tech solutions from a range of different companies, not just those within General Catalyst’s portfolio. The tech companies HATCo taps to use within Summa will be on the mature side, not early-stage startups, Harrison added. 

As part of the acquisition, Summa will switch from a non-profit to a for-profit organization. The health system said that once the deal closes, the remaining funds will be used to support a new health-focused community foundation for the greater Akron area.  

“We will be able to invest in and grow our team in ways we could not achieve as an independent organization,” Summa executives said in the release. “And while the structure and model of Summa Health will shift when we become part of HATCo, our priorities will not change and our providers, employees and leadership team will transition to the new entity.” 

The deal is still subject to regulatory approval. Representatives for General Catalyst and Summa did not immediately respond to requests for comment. 

Read more about why HATCo is acquiring Summa here.

Feel free to send any tips, suggestions, story ideas and data to Ashley at ashley.capoot@nbcuni.com.

]]>
https://thenewshub.in/2024/11/13/healthy-returns-astrazeneca-expands-u-s-investment-plan-on-confidence-in-economy/feed/ 0
How Trump's victory could change abortion rights in America https://thenewshub.in/2024/11/07/how-trumps-victory-could-change-abortion-rights-in-america/ https://thenewshub.in/2024/11/07/how-trumps-victory-could-change-abortion-rights-in-america/?noamp=mobile#respond Thu, 07 Nov 2024 20:00:01 +0000 https://thenewshub.in/2024/11/07/how-trumps-victory-could-change-abortion-rights-in-america/

Anti-abortion demonstrators listen to President Donald Trump as he speaks at the 47th annual “March for Life” in Washington, D.C., Jan. 24, 2020.

Olivier Douliery | Afp | Getty Images

Voters in seven out of 10 states approved ballot measures this week to safeguard abortion rights, a hot-button issue that helped drive Americans to the polls.

But President-elect Donald Trump‘s victory early Wednesday could make access to the procedure more vulnerable and uncertain across the U.S., health policy experts warned, leaving the reproductive well-being of many women hanging in the balance.

Trump has waffled considerably on his position on abortion, most recently saying he would not support a federal ban and wants to leave the issue up to the states. But Trump and his appointees to federal agencies could further restrict abortion on the federal level through methods that won’t require Congress to pass new legislation.

“The more restrictions we see on abortion over the next four years, the worse health outcomes are going to be. People are suffering and dying unnecessarily,” said Katie O’Connor, senior director of federal abortion policy at the National Women’s Law Center.

Abortion access in the U.S. has already been in a state of flux in the two years since the Supreme Court overturned Roe v. Wade and ended the federal constitutional right to the procedure — a decision Trump takes credit for since he reshaped the court. As of last year, more than 25 million women ages 15 to 44 lived in states where there are more restrictions on abortion than before the court’s ruling in 2022, PBS reported.

Experts say a further crackdown on abortion by the Trump administration could put the health of many patients, especially those who are lower-income or people of color, at risk.

“As long as we have a government that is not fully committed to abortion access for everyone who seeks it, there is going to be chaos and confusion on the ground around what is legal and what is available,” O’Connor said. “It’s going to contribute to the ongoing health-care access crisis we’re seeing with abortion.”‘

It’s unclear what Trump’s actions around the issue could look like. There is little public support for Congress to pass nationwide bans on abortion, according to a poll conducted in June by The Associated Press-NORC Center for Public Affairs Research. At least 70% of Americans oppose a federal ban on abortion or a ban on the procedure at six weeks.

If Trump does decide to curb access, experts say, that could include limiting the use of medication abortion, particularly when it is administered through telehealth or delivered by mail. 

Medication is the most common method used to end a pregnancy in the U.S., accounting for 63% of all abortions in the U.S. last year, according to a March study by the Guttmacher Institute, a research organization that supports abortion access. 

Trump’s campaign did not immediately respond to a request for comment.

he had no plans to enforce the Comstock Act. 

But anti-abortion advocates and people in Trump’s close circle, including his running mate, Vice President-elect JD Vance, have urged the opposite. Some of Trump’s former advisors, writing in the conservative policy blueprint Project 2025, also endorse the use of the Comstock Act to restrict abortion pills. So does every major anti-abortion organization in the country.

There would likely be legal opposition to any effort to enforce it, O’Connor noted. 

That issue could end up at the Supreme Court, whose justices have expressed openness to the idea that the Comstock Act could ban abortion. Earlier this year, Justices Samuel Alito and Clarence Thomas repeatedly invoked the Comstock Act during oral arguments in a case regarding medication abortion. 

dismissed the challenge to mifepristone and sided with the Biden administration, meaning the commonly used medication could remain widely available.

Mifepristone and Misoprostol pills are pictured Wednesday, Oct. 3, 2018, in Skokie, Illinois.

Erin Hooley | Chicago Tribune | Tribune News Service | Getty Images

But Trump’s FDA appointees could push to roll back certain changes made from 2016 to 2021 that expanded access to mifepristone. That could include reinstating requirements that would require mifepristone to be dispensed in person, which would effectively eliminate access to the pill via telehealth. 

Telehealth has become an increasingly common way to access abortion bills, accounting for nearly 1 in 5 of them during the last months of 2023, according to a research project published in May by the Society of Family Planning. 

Restricting telehealth as an option would have an “incredibly chilling effect” on abortion access,” said Alina Salganicoff, a senior vice president and the director of Women’s Health Policy at KFF, a health policy research organization. 

“We will likely see more people in states where abortion is banned having to travel, more delays in getting care and the potential for more of them actually being denied that care due to difficulties related to getting the procedure in person,” she said. 

New FDA leaders could also attempt to use a more extreme approach: rescinding mifepristone’s approval altogether. Either strategy would disregard significant scientific research demonstrating mifepristone’s safe and effective use in the U.S., experts said.

Trump vaguely suggested in August that he would not rule out directing the FDA to revoke access to mifepristone. Just days later, Vance attempted to walk back those remarks. 

Trump’s comments appear to be a shift from his stance in June, when the former president said during a CNN debate that he “will not block” access to mifepristone.

Reviving old rules, gutting Biden’s

At the very least, Trump could reinstate some of the policies implemented during his first term that made abortions harder to obtain and gut some of the efforts that the Biden administration used to expand access. 

Rep. Lois Frankel, D-Fla., left, points out states with restricted reproductive rights as Rep. Joyce Beatty, D-Ohio, and Rep. Joe Neguse, D-Colo., hold the map during a news conference on reproductive rights in the U.S. Capitol on Wednesday, May 8, 2024. 

Bill Clark | Cq-roll Call, Inc. | Getty Images

Trump could reinstate a so-called domestic gag rule, which he implemented in 2019 and that the Biden administration reversed in 2021.

The rule prohibited providers that are part of the federally funded Title X family program from referring patients for abortion care or providing counseling that includes abortion information. Title X is a decades-old program that provides family planning and preventive health services to patients, especially lower-income individuals. 

Guttmacher’s Baden said the rule “decimated” Title X’s network of family planning clinics and constrained its ability to serve low-income patients. She said those clinics are “still recovering from that.” 

“I see no reason to assume that he wouldn’t go back to reinstating that rule in the first 100 days,” Baden said.

A Trump administration could also quickly nullify some of Biden’s executive orders, memorandums and other efforts that aimed to protect and expand access to reproductive health services, according to Baden. 

]]>
https://thenewshub.in/2024/11/07/how-trumps-victory-could-change-abortion-rights-in-america/feed/ 0
FDA proposes ending use of decongestant found in many cold, allergy medicines https://thenewshub.in/2024/11/07/fda-proposes-ending-use-of-decongestant-found-in-many-cold-allergy-medicines/ https://thenewshub.in/2024/11/07/fda-proposes-ending-use-of-decongestant-found-in-many-cold-allergy-medicines/?noamp=mobile#respond Thu, 07 Nov 2024 16:28:46 +0000 https://thenewshub.in/2024/11/07/fda-proposes-ending-use-of-decongestant-found-in-many-cold-allergy-medicines/

A bottle of Vicks DayQuil cold and flu medicine containing phenylephrine is displayed for sale in a CVS Pharmacy store in Hawthorne, California, on Sept. 12, 2023.

Patrick T. Fallon | AFP | Getty Images

The Food and Drug Administration on Thursday proposed ending the use of a common ingredient found in many popular over-the-counter cold and allergy medications.

The agency said an extensive review of available data determined that the ingredient, oral phenylephrine, doesn’t actually relieve nasal congestion. It comes more than a year after advisors to the FDA unanimously reached the same conclusion.

Based on the data, “we are taking this next step in the process to propose removing oral phenylephrine because it is not effective as a nasal decongestant,” Dr. Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a release.

The FDA said the proposed order is not based on safety concerns and is not final yet, which means companies can still market over-the-counter drugs containing oral phenylephrine for now. But a final decision would force pharmacies to clear shelves of hundreds of products containing oral forms of the ingredient, which is found in versions of drugs such as NyQuil, Benadryl, Sudafed and Mucinex.

Last year, CVS said it has already moved to pull certain medicines containing oral phenylephrine.

A final order would also require drugmakers such as Procter & Gamble, Bayer, and Johnson & Johnson spinoff Kenvue to reformulate many of their oral cold and allergy products. 

Phenylephrine is thought to relieve congestion by reducing the swelling of blood vessels in the nasal passages. Without oral phenylephrine on the market, patients will likely scramble to seek out spray versions of the drug, or other medications with different ingredients, both of which the FDA’s decision does not affect.

Retail stores such as CVS and Walgreens could also take a hit: Those stores sold 242 million bottles of drugs containing phenylephrine in 2022, which generated nearly $1.8 billion in sales, according to a presentation by FDA staff last year.

The FDA could specifically revoke the drug’s over-the-counter designation as “generally recognized as safe and effective.” The designation, typically used for older medicines, allows drugmakers to include an ingredient in over-the-counter products without the need to file an FDA application.

The meeting of FDA advisors last year was prompted by researchers at the University of Florida, who petitioned the agency to remove phenylephrine products from the market based on studies showing they failed to outperform placebo pills in patients with cold and allergy congestion. 

The same researchers also challenged the drug’s effectiveness in 2007, but the FDA allowed the products to remain on the market pending additional research.

However, FDA staff, in briefing documents posted ahead of the panel meeting last year, concluded that oral formulations of phenylephrine don’t work at standard or even higher doses. The staff said only a very small amount of phenylephrine actually reaches the nose to relieve congestion. 

Representatives for the Consumer Healthcare Products Association, a group that represents over-the-counter drug manufacturers, did not offer any new evidence to counter the FDA staff’s conclusion about phenylephrine during the meeting last year.

But the group argued that pulling oral phenylephrine from the market would be a significant burden to consumers.

The group shared a survey that found 1 in 2 households in the U.S. used an oral decongestant over the last year. It also found people prefer oral decongestants over nasal spray by a 3-to-1 margin.

Phenylephrine became the main decongestant in over-the-counter cold and allergy medicines in 2006, when sales of another decongestant, pseudoephedrine, were restricted in the U.S. 

Pseudoephedrine was moved behind the pharmacy counter because it can be misused to make methamphetamine, a highly addictive stimulant drug that affects the central nervous system. 

]]>
https://thenewshub.in/2024/11/07/fda-proposes-ending-use-of-decongestant-found-in-many-cold-allergy-medicines/feed/ 0
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold  https://thenewshub.in/2024/11/07/moderna-posts-surprise-profit-as-covid-vaccine-sales-impress-cost-cuts-take-hold/ https://thenewshub.in/2024/11/07/moderna-posts-surprise-profit-as-covid-vaccine-sales-impress-cost-cuts-take-hold/?noamp=mobile#respond Thu, 07 Nov 2024 11:34:31 +0000 https://thenewshub.in/2024/11/07/moderna-posts-surprise-profit-as-covid-vaccine-sales-impress-cost-cuts-take-hold/

Moderna on Thursday posted a surprise profit for the third quarter, smashing Wall Street estimates, as its cost-cutting efforts took hold and sales of its Covid vaccine came in higher than expected. 

The biotech company posted a net income of $13 million, or 3 cents per share, for the third quarter. That compares with a net loss of $3.63 billion, or $9.53 cents per share, reported for the year-ago period.

Moderna is slashing expenses, with a recently announced goal of achieving $1.1 billion in savings by 2027, as it tries to recover from the rapid decline of its Covid business. It is the first quarter that includes sales of Moderna’s vaccine against respiratory syncytial virus, or RSV, its second-ever commercially available product. 

Before year end, the company plans to file for approval of its experimental “next-generation” Covid vaccine and combination shot targeting Covid and the flu. Moderna this year also expects to apply for expanded approval of its RSV vaccine, targeting high-risk adults ages 18 to 59. 

Moderna said Thursday its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023, which allowed the biotech company to “meet demand more effectively.” The company was able to ship out doses to pharmacies and healthcare providers and reach the arms of more patients sooner. 

“I think the earlier launch and a steeper ramp drove a much higher sales number” for the Covid vaccine, Moderna CEO Stéphane Bancel said in an interview. During the first week of the vaccine’s launch, the company shipped twice as many products globally than it did in 2023, Bancel noted. 

He added that “this was a big cost reduction quarter, and we’re going to continue to do that.” 

Here’s what Moderna reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:

  • Earnings per share: 3 cents vs. an expected loss of $1.90
  • Revenue: $1.86 billion vs. $1.25 billion expected

Moderna booked third-quarter sales of $1.86 billion, only slightly higher than the $1.83 billion in revenue it recorded during the same period a year ago. The vast majority of that total came from its Covid shot, including $1.2 billion in U.S. sales and roughly $600 million from international markets. 

The company’s third-quarter revenue also included $10 million in U.S. sales of its RSV shot, which won approval in May. Moderna said that sales of that shot were lower than expected since it was approved and recommended by regulators later in the contracting season, when many vaccine distributors had already completed their orders. 

Analysts had expected sales of $132 million for the RSV vaccine, according to estimates compiled by StreetAccount. Moderna’s RSV shot is so far approved in the U.S., European Union, Norway, Iceland and Qatar. 

The company reiterated its full-year 2024 product sales guidance of roughly $3 billion to $3.5 billion. Last quarter, Moderna slashed its outlook on lower expected sales in Europe, a “competitive environment” for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025. 

Shares of Moderna are down almost 50% this year as investors mull over its path forward after Covid. The company is betting on a pipeline built around its messenger RNA platform, which is the technology used in its Covid vaccine and RSV shot. 

The biotech company currently has 45 products in development, and expects to bring 10 of them to the market over the next three years. 

Moderna is developing a standalone flu shot, a personalized cancer vaccine with Merck and shots for latent viruses, among other products.

Cost of sales for the third quarter was $514 million, down 77% from the same period a year ago. That includes $214 million in write-downs of unused doses of the Covid vaccine and $27 million in charges related to the company’s efforts to scale back its manufacturing footprint, among other costs. 

Research and development expenses decreased by 2% to $1.1 billion compared with the same period in 2023. Moderna said that decline was primarily due to lower clinical development and manufacturing expenses, citing decreased spending on clinical trials, among other factors.

Meanwhile, selling, general and administrative expenses for the period fell by 36% to $281 million compared with the third quarter of 2023. SG&A expenses usually include the costs of promoting, selling and delivering a company’s products and services.

]]>
https://thenewshub.in/2024/11/07/moderna-posts-surprise-profit-as-covid-vaccine-sales-impress-cost-cuts-take-hold/feed/ 0
What Trump's election to the White House could mean for EVs https://thenewshub.in/2024/11/06/what-trumps-election-to-the-white-house-could-mean-for-evs/ https://thenewshub.in/2024/11/06/what-trumps-election-to-the-white-house-could-mean-for-evs/?noamp=mobile#respond Wed, 06 Nov 2024 21:19:02 +0000 https://thenewshub.in/2024/11/06/what-trumps-election-to-the-white-house-could-mean-for-evs/

Production is now set to begin at the former Detroit-Hamtramck assembly plant, less than two years after GM announced the massive $2.2 billion investment to fully renovate the facility to build a variety of all-electric trucks and SUVs.

Photo by Jeffrey Sauger for General Motors

DETROIT – President-elect Donald Trump’s victory over Vice President Kamala Harris is expected to send the U.S. electric vehicle industry into a period of uncertainty.

Republicans, led by the former president, have largely condemned EVs, claiming they are being forced upon consumers. Trump has vowed to roll back or eliminate many vehicle emissions standards under the Environmental Protection Agency as well as incentives to promote production and adoption of the vehicles such as the Biden administration’s Inflation Reduction Act of 2022.

Auto industry insiders and other officials have said it would be difficult for Trump to completely gut the IRA, but he could defund or limit EV subsidies through executive orders or other policy actions.

Several people said they would expect Trump to target federal consumer credits that currently offer up to $7,500 for the purchase of an EV rather than target industrial production credits for companies.

“The IRA will probably have some adjustments … I don’t think the IRA will go away,” David Rubenstein, co-founder and co-chairman of The Carlyle Group investment firm, told CNBC on Wednesday. “It has some really good things in it that I think Republicans and Democrats will like.”

Many of the investments into EV production under the IRA having been taking place in Republican states such as Ohio, South Carolina and Georgia.

Automotive executives are also quick to say they don’t base investment decisions on who holds the White House, but there are natural adjustments with new administrations.

“Anytime there’s an administration change, it’s an interesting time for the industry because we have to go through new policies and regulations and have to bring new people up to speed on who we are and what we do,” David Christ, group vice president and general manager of the Toyota Division in North America, said Wednesday during an Automotive Press Association event near Detroit. “Administrations sometimes change every four years, so we don’t really do a lot of modifying the strategy.”

General Motors, Ford Motor and Chrysler parent Stellantis — would be the biggest winners of a second Trump term and Republican control of Congress.

“We see F and GM as the main beneficiaries from the Trump administration,” BofA Securities analyst John Murphy said in a Wednesday investor note. “The current environmental regime would pressure the core business of legacy [automakers, trucks,] to decarbonize by the end of the decade while shifting quickly to an EV portfolio.”

GM’s aspirations for an “all-electric future” and profitable EV business in the near term are highly reliant on federal tax credits.

Analysts had indicated EV startups such as Rivian Automotive and Lucid Group would benefit more with a Democratic win.

Toyota could also be a winner if EV regulations are reduced or eliminated, as the Japanese automaker has been slow to invest in all-electric models compared to hybrid vehicles.

Shares of GM and Ford closed Wednesday up 2.5% and 5.6%, respectively. Stock prices for Toyota and Stellantis, which is experiencing significant problems in the U.S., were essentially level. Lucid and Rivian were each down, 5.3% and 8.3%, respectively.

Stock Chart IconStock chart icon

hide content

Shares of automakers after President-elect Donald Trump’s victory.

An outlier is U.S. electric vehicle leader Tesla. CEO Elon Musk heavily campaigned in swing states for Trump, who has discussed making the billionaire a government efficiency czar.

Shares of Tesla soared Wednesday by 15% and earlier notched a new 52-week high.

“We see RIVN and LCID challenged, which is largely reflected in the stocks,” Murphy said. “We don’t expect meaningful issues for TSLA since it has already reached profitability and will introduce more entry level products that could be attractive for the larger public.”

Several automakers did not immediately return request for comment after NBC News and several other media outlets called the election for Trump.

Others such as the Detroit automakers and Hyundai Motor congratulated Trump and the newly elected officials across all levels of government.

“We look forward to working with the new Administration and Congress on policies that strengthen the U.S. automotive industry, which supports 9.7 million American jobs and drives more than $1 trillion into the economy each year,” Ford said.

“We congratulate and look forward to working with the President-elect, Congress, and all elected officials to ensure that the U.S. continues to lead the world in technology and innovation, to the benefit of American workers and consumers alike,” GM said.

“Advanced Clean Cars II” regulations of 2022 call for 35% of 2026 model year vehicles, which will begin to be introduced next year, to be zero-emission vehicles. Battery-electric, fuel cell and, to an extent, plug-in hybrid electric vehicles qualify as zero emission.

Before the election, automotive officials said regardless of who won the White House, many automakers will push for the mandates to be postponed.

The California Air Resources Board reports 12 states and Washington, D.C., have adopted the rules; however, roughly half of them did so starting with the 2027 model year. They are part of CARB’s Advanced Clean Cars regulations that require 100% of new vehicle sales in the state of California to be zero-emission models by 2035.

EVs made up 10% or more of local market shares in just 11 states and the District of Columbia to begin this year, according to the Alliance for Automotive Innovation, a trade association and lobby group that represents most major automakers operating in the U.S.

Auto executives and industry experts also expect Trump could roll back or freeze the Corporate Average Fuel Economy, or CAFE, standards for model years 2027-2031.

Don’t miss these insights from CNBC PRO

]]> https://thenewshub.in/2024/11/06/what-trumps-election-to-the-white-house-could-mean-for-evs/feed/ 0 Donald Trump's victory: Future of fashion in US https://thenewshub.in/2024/11/06/donald-trumps-victory-future-of-fashion-in-us/ https://thenewshub.in/2024/11/06/donald-trumps-victory-future-of-fashion-in-us/?noamp=mobile#respond Wed, 06 Nov 2024 12:30:00 +0000 https://thenewshub.in/2024/11/06/donald-trumps-victory-future-of-fashion-in-us/

Donald Trump has won the US Presidential election, and this win will definitely influence the country’s trade and business sectors, including the fashion industry. Trup is known for his ‘America First; stance, and his policies are likely to emphasise more on domestic production, restructuring tariffs, taxes, and trade agreements. These changes will affect the fashion brands that depend on international supply chains but will also change consumer pricing, availability, and industry practices. Let’s take a better view of what might lie ahead for the United States fashion industry by considering the trade policies of Donald Trump and also have a speculative look at what things might have looked like under a Kamala Harris administration.

Five reasons why Donald Trump can win US presidential election

Trump at a campaign stop 2024 US Election

Trump’s ‘America First’ policies and their impact on fashion
The Donald Trump administration has always taken enormous interest in transforming trade policies to support the American product. During his first gig as the President of America, his campaign of ‘America First’ aimed to strengthen domestic producers and minimise the country’s dependence on overseas products at large, as is the case with most fashion brands. Tariffs, a centrepiece of his trade policy, directly impacted the cost and sourcing of raw materials and manufactured goods for fashion brands across the US. These tariffs often covered key inputs like textiles, clothing, and accessories, which are typically sourced from Asia, especially China.

LIVE | US President-Elect Trump FULL Victory Speech | ‘We Made History’ | Florida LIVE

The intention of the policy was to bring back more fashion manufacturing jobs into the US. Reality, however, proved otherwise. Although tariffs are expected to boost domestic manufacturing, most of the brands could not find a big manufacturing facility for their ready-to-wear apparel due to infrastructure and high-cost issues associated with running an apparel manufacturing facility in the US. Most the brands were consequently faced with an increased cost of production they either pass on to their consumers or absorb at personal cost.
That scaled back their pricing structures or compromised on the range and quality of materials adopted. Fast fashion brands were unable to sustain their appeal of low cost due to a rise in costs for importing. This meant both luxury and affordable brands succumbed financially, but some smaller brand went under due to lack of ability to meet higher production costs.

Donald Trump

Donald Trump

The goal was to bring in more fashion manufacturing jobs in the US. But things turned out a tad too complicated for that reason alone. Even though it intended to make domestic production more attractive, high cost factors and the absence of such infrastructure in the country as far as large apparel manufacturers are concerned made a turnaround unattractive on behalf of most brands coming home without raising the overall costs. As a consequence, production became more costly for them, and most of these brands either passed this along to their customers or absorbed it themselves in the form of reduced profit margins.
This meant, therefore, that luxury brands of fashion and high-class retailers would have to trim down their price structures or reduce the scope and grade of material they used. Conversely, fast fashion brands suffered the pressure of losing their ‘value for money’ by rising import costs. Eventually, the new production costs presented both the luxury and economy brands with financial stress, to which some smaller brands ultimately closed down.

Donald Trump and Melania Trump

Donald Trump and Melania Trump

Tariffs and taxes on imports: A mixed bag
Under Trump, the United States placed tariffs on goods from several countries, targeting China in particular, which represents a large share of raw materials and finished goods used by American fashion brands. The tariffs were placed on billions of dollars’ worth of Chinese goods, which include various textiles, clothing, and accessories.
For some of these companies, the tariffs multiplied the price paid for raw materials, stripping off profits or forcing brands to raise prices to consumers. Large brands- Nike and Levi’s-diversified their manufacturing base across different countries. They easily arranged for shifting their production units to other geographic locations, such as Vietnam or Mexico. The smaller brands had it tougher. Many had to find other places to manufacture products, an expensive and time-consuming process involving renegotiating contracts, finding new suppliers, and adjusting to the new production environment.
Changes had the effect of making items on clothing and accessories costlier for consumers, especially on brands that had no other choice but to pass those extra costs down the line. This made it an incredibly difficult landscape for the US. fashion market in terms of brands and consumers trying to adapt to higher costs of fashion items.

donald trump election

ડોનાલ્ડ ટ્રમ્પ ફરી એક વખત યુએસ પ્રેસિડન્ટ બને તેવી શક્યતા છે.

Made in USA, a distant dream?
Infrastructure on textiles and apparel in manufacturing sectors has declined over time when such production was outsourced because it was cheaper elsewhere. However, with renewed vigour toward domestic manufacturing, this could not be adequately answered for a number of infrastructural, skilled workforce needs, and capacity reasons-especially given the sensitivity in apparel markets to prices-paying high prices for apparel as much as possible. Plus, the cost of garments and apparels produced within America would be significantly more costly compared to other nations as well, where the overhead cost of labor and making was relatively lower.
Brands that attempted to produce domestically often found it challenging to compete with the affordability of imported goods. For instance, denim production in the US can cost two to three times more than in countries like Bangladesh or China. As a result, only high-end or niche brands were able to adopt the ‘Made in the USA’ label without losing their competitive edge.

US Elections: World leaders congratulate Donald Trump

Donald Trump

How the fashion industry adapted
The fashion industry sought creative changes in order to adapt to the new landscape of trade. Many brands started looking to diversify their supply chains, reducing dependence on China and shifting production towards countries with favorable trade agreements such as Vietnam, Indonesia, and India. The tendency continues to grow as more and more brands seek ways to avoid tariffs and reduce production costs.
Some companies began a nearshoring strategy by bringing operations closer to the United States in places such as Mexico or through Central America. The nearshoring option allows brands to maintain supply lines that are shorter than from Asia; however, it means going up against different kinds of logistical hurdles and, often, slightly higher production costs from Asia. Besides this, many brands are investing in sustainable practices and using materials that appeal to their growing consumer base that finds value in environmental responsibility while using this shift as an opportunity to market their services as potentially more expensive.

US elections 2024: North Carolina man wanted to vote for Trump instead voted for Harris because girlfriend threatened to break up with him

Donald Trump

Advantages and disadvantages of Trump’s policies toward the fashion industry
Benefits
Boosting local brands: Trump’s policies focus on the production of more locally manufactured items, thus boosting those firms that already were using more of local products or could now shift their production.
Less vulnerability in supply chain: In the past, imposing tariffs on the products from China led the firms to diversify their supply chain so that in the future any such disturbance may not again create the same type of problem for them.
Drawbacks
Increased production cost: If Trump sticks to his old plan, then the prices of buying imported products will rise, and things may become unaffordable for the consumers.
Economic uncertainty: Under Trump’s rule, constant changes in trade policies created uncertainty, complicating long-term planning and budgeting for many companies.
Reduced market growth: Higher prices due to tariffs will limit consumer purchasing power, especially for fast fashion brands that rely on low-cost goods.

Donald trump

How Kamala Harris’ Presidency may have affected fashion commerce
Had Kamala Harris become the president instead of Donald Trump, the fashion trade could have seen a different terrain. Harris has frequently championed free trade and economic policies that focus on inclusivity and sustainability. Her administration might have taken a more cooperative approach to trade with nations like China and in the multilateral trade agreements. This would have meant much stability for the industry.
Harris’s approach to fashion trade likely would have emphasised sustainable practices, and her administration might have introduced incentives for brands that prioritise ethical labour practices and environmental responsibility. For example, instead of tariffs, Harris might have encouraged companies to shift toward sustainable fabrics and production methods through tax breaks or grants. This could have provided both economic and environmental benefits, appealing to a growing consumer base that values eco-conscious practices.

Kamala-Harris

Furthermore, as a woman of colour and a daughter of immigrants, Harris may have fostered stronger relationships with Asian countries, including India, where a large portion of textile production occurs. This would have facilitated smoother trade relationships and helped maintain affordability for fashion imports.



]]>
https://thenewshub.in/2024/11/06/donald-trumps-victory-future-of-fashion-in-us/feed/ 0
Why flights to Europe are the cheapest they've been in years https://thenewshub.in/2024/11/03/why-flights-to-europe-are-the-cheapest-theyve-been-in-years/ https://thenewshub.in/2024/11/03/why-flights-to-europe-are-the-cheapest-theyve-been-in-years/?noamp=mobile#respond Sun, 03 Nov 2024 13:00:01 +0000 https://thenewshub.in/2024/11/03/why-flights-to-europe-are-the-cheapest-theyve-been-in-years/

A tourist takes a photo as the Acropolis’ Propylaea are seen in the background, in Athens, Greece, on June 28, 2024.

Elias Marcou | Reuters

Flights between the U.S. and Europe have not been this cheap in three years, when many countries were just lifting Covid-19 era rules.

Fares are low even for the traditionally slow late-fall and winter months outside of major holidays.

“It is brutal to fill seats during these times of year,” said Brett Snyder, who writes the Cranky Flier travel industry site.

According to flight-tracking company Hopper, “good deal” fares across the Atlantic to Europe are averaging $578 in November, down from $619 a year earlier.

It is the lowest deal fare for this month since 2021, when they were going for $479 and much of international travel was in a slump because of the pandemic, Hopper data shows.

In January, after the year-end holidays, 2025 fares are even lower: $558 compared to $578 for the same month in 2024, though higher than $488 in January 2022, according to Hopper.

U.S. domestic airfare, on the other hand, is more expensive compared with last year in every month from November through March.

Many airlines from financially troubled Spirit Airlines to profitable Southwest Airlines have cut flights or trimmed growth plans into next year, which has helped keep U.S. fares firm. Aircraft scarcity is also limiting airlines from adding many flights.

There are also some periods of weaker demand overall, executives at the largest U.S. carriers, Delta Air Lines, United Airlines and American Airlines have said, calling out the week before and after the U.S. presidential election on Tuesday.

shoulder-season demand to Europe as travelers look to escape scorching summer temperatures and crowds. As a result, they have also added flights outside of peak periods.

Airline capacity between the U.S. and Europe in the fourth quarter is marginally lower than last year, but it is higher than in 2019 and nearly double the amount in the same period of 2021, according to Cirium.

“I expect airfare [to Europe] to be low into next year,” said Hayley Berg, Hopper’s lead economist.

Now, on the heels of two big years for European travel, many customers are fresh off their big trips to popular destinations such as Spain and Italy, which means fewer people to fill seats in the offseason.

“It’s not as though there is so much low-hanging fruit and where airlines could print money hand-over-fist like last year,” said Scott Keyes, founder of travel app Going, which was previously known as Scott’s Cheap Flights.

Airlines traditionally discount flights in the offseason, but they are even cheaper this year.

“That’s the tell,” Keyes said. “When they’re having to go out and discount, they’re having to juice the demand.”

So that travelers do not get bored with European vacation mainstays when next year’s peak warm-weather travel season rolls around, airlines are trying new things. United Airlines has noted many customers have already taken trips to major European cities and the airline plans to expand its schedule next year to more off-the-beaten-path destinations such as Greenland and Mongolia.

“We’re also able to do just as well financially outside of our partner hubs,” United’s Chief Commercial Officer Andrew Nocella said on an earnings call last month. “So we look across the globe, we look for new destinations, we look for hot destinations and destinations, most importantly, we can make money in.”

Don’t miss these insights from CNBC PRO

]]>
https://thenewshub.in/2024/11/03/why-flights-to-europe-are-the-cheapest-theyve-been-in-years/feed/ 0
Japan, US, S.Korea conduct joint drills after N.Korea's ICBM launch https://thenewshub.in/2024/11/03/japan-us-s-korea-conduct-joint-drills-after-n-koreas-icbm-launch/ https://thenewshub.in/2024/11/03/japan-us-s-korea-conduct-joint-drills-after-n-koreas-icbm-launch/?noamp=mobile#respond Sun, 03 Nov 2024 12:27:11 +0000 https://thenewshub.in/2024/11/03/japan-us-s-korea-conduct-joint-drills-after-n-koreas-icbm-launch/

South Korea, Japan, and the United States have conducted a joint air drill involving a heavy bomber, Seoul’s military said, in response to North Korea’s latest long-range missile test.

The exercise took place on Sunday, three days after Pyongyang launched one of its most powerful and advanced solid-fuelled intercontinental ballistic missiles (ICBM), which experts say could reach targets in the mainland US.

The drill mobilised the US’ B-1B bomber, South Korea’s F-15K and KF-16 fighter jets, and Japan’s F-2 jets, Seoul’s military said.

“The exercise demonstrates the commitment of the ROK-US alliance to integrated extended deterrence in response to the advancing nuclear and missile threats from North Korea,” said South Korea’s Joint Chiefs of Staff in a press release.

During the aerial manoeuvre, South Korea and Japan’s jets escorted the US strategic bomber to a designated location south of the Korean peninsula, “demonstrating an overwhelming capability to swiftly and accurately strike simulated targets,” it added.

The B-1B Lancer is a supersonic heavy bomber known for its high-speed performance with a payload of 34,000 kilograms of munitions, including both conventional and precision-guided weapons.

It was the fourth time this year the bomber was deployed to the Korean peninsula, the military said, and the second time for a trilateral aerial exercise to counter Pyongyang’s military threats.

The North’s latest ICBM launch is said to have flown higher and further than any previous missile, according to North Korea as well as Seoul and Tokyo’s militaries, which tracked it in real-time.

The official Korean Central News Agency hailed it as “the world’s strongest strategic missile,” and leader Kim “expressed great satisfaction” at the successful launch.

North Korea “would never change its line of bolstering up its nuclear forces,” the agency said.

The launch came amid growing international scrutiny over Pyongyang’s purported deployment of thousands of troops to Russia to support Moscow’s war efforts in Ukraine, raising concerns North Korean soldiers in Russian uniforms could soon engage in combat.

]]>
https://thenewshub.in/2024/11/03/japan-us-s-korea-conduct-joint-drills-after-n-koreas-icbm-launch/feed/ 0
Boeing union backs sweetened contract offer that could end strike, sets vote for Monday https://thenewshub.in/2024/11/01/boeing-union-backs-sweetened-contract-offer-that-could-end-strike-sets-vote-for-monday/ https://thenewshub.in/2024/11/01/boeing-union-backs-sweetened-contract-offer-that-could-end-strike-sets-vote-for-monday/?noamp=mobile#respond Fri, 01 Nov 2024 18:41:54 +0000 https://thenewshub.in/2024/11/01/boeing-union-backs-sweetened-contract-offer-that-could-end-strike-sets-vote-for-monday/

Boeing workers from the International Association of Machinists and Aerospace Workers District 751 gather on a picket line near the entrance to a Boeing production facility on the day of a vote on a new contract proposal during an ongoing strike in Renton, Washington, U.S. October 23, 2024. 

David Ryder | Reuters

Boeing and its machinists’ union have agreed on a new negotiated offer to raise worker pay and potentially end a crippling strike that began seven weeks ago with a vote on the new proposal set for Monday.

The union urged workers to approve the contract. Getting workers back into factories is urgent for Boeing as it faces mounting losses.

“In every negotiation and strike, there is a point where we have extracted everything that we can in bargaining and by withholding our labor,” the International Association of Machinists and Aerospace Workers District 751 said Thursday. “We are at that point now and risk a regressive or lesser offer in the future.”

The new proposal includes 38% general wage increases over four years, up from a previous offer for 35%, bringing the compounding pay increases to close to 44%, the union said Thursday. It also gives workers the option of a $12,000 one-time ratification bonus or to choose a previous offer for a $7,000 ratification bonus and a $5,000 401(k) contribution.

The union said that asking its members to stay on strike longer “wouldn’t be right as we have achieved so much success.”

Boeing’s more than 32,000 machinists, mostly based in the Seattle area, walked off the job on Sept. 13 after turning down a tentative agreement. They rejected another proposal earlier this month, extending the strike.

Boeing said Thursday that at the end of the contract, machinist pay will average $119,309.

“It’s time we all come back together and focus on rebuilding the business and delivering the world’s best airplanes,” Boeing’s CEO Kelly Ortberg said in a note to staff on Friday. “There are a lot of people depending on us.”

He urged workers to vote “since the results of the vote will affect all of us.”

The Biden administration has gotten involved in negotiations during the strike, which has halted most aircraft production at Boeing, a top U.S. exporter. Acting Labor Secretary Julie Su met with the company and the union this week.

The Boeing strike took a bite out of U.S. employment numbers in October, according to Friday’s U.S. jobs report, the last before the Nov. 5 presidential election.

President Joe Biden congratulated the union and Boeing for the new contract proposal.

“Machinists at Boeing have sacrificed over the years and deserve a strong contract,” he said in a statement on Friday, shortly after the jobs report was released.

Read more CNBC airline news

Ortberg said on his first earnings call last week since taking the top job in August that the company has been “feverishly working to find a solution that works for the company and meets our employees’ needs.” Hours later, the workers rejected a negotiated proposal.

Boeing machinists have repeatedly pushed for higher compensation as the cost of living in the Seattle area — where technology giants like Microsoft and Amazon have ramped up staffing — has surged in recent years.

Under the new contract proposal, as in previous iterations, Boeing vowed to build whatever its next airplane will be in the Puget Sound area. One sore spot among workers is that Boeing moved 787 Dreamliner production to a non-union factory in South Carolina.

The strike has further pushed back Boeing leaders’ plans to stabilize the aerospace behemoth as it reels from the impact of production flaws and the fallout from safety issues, most recently a door plug that blew out midair from a Boeing 737 Max 9 at the start of the year.

Boeing lost more than $6 billion in the last quarter and warned it would continue to burn cash through 2025.

Don’t miss these insights from CNBC PRO

]]>
https://thenewshub.in/2024/11/01/boeing-union-backs-sweetened-contract-offer-that-could-end-strike-sets-vote-for-monday/feed/ 0